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GLOSSARY 
Neurofeedback: a procedure wherein individuals learn to modulate real-time signals from their 
own brain activity; often leveraged to self-regulate neural processes for therapeutic ends. 
Schabus et al. investigated electroencephalography neurofeedback. This technique records 
electrical brain activity from sensors placed on the scalp and remains the most popular form of 
neurofeedback. 
Sham neurofeedback: feedback from an unrelated brain signal or from the brain of another 
participant; employed as a control condition to isolate the specific influence of genuine feedback.  
Superplacebo: A treatment that is actually a placebo although neither the prescribing practitioner 
nor the receiving patient is aware of the absence of evidence to recommend it therapeutically. 
 
MAIN TEXT 
Neurofeedback ranks high on the list of ostensibly “scientific” tools available for 
moulding brain function and bolstering mental processes. And yet, as with other popular 
techniques such as computerized brain games, a dearth of robust evidence and well-controlled 
studies characterizes the research sphere of neurofeedback. In this issue of Brain, Schabus et al. 
(2017) report a carefully crafted experiment probing the treatment of insomnia; their findings 
suggest that the benefits of neurofeedback may derive largely from placebo-like effects. 
In neurofeedback, participants attempt to self-regulate an ongoing feedback signal from 
their own brain activity (Sitaram et al., 2016). Since the inception of this field in 1958, the 
dominant theory has contended that neurofeedback endows individuals with volitional control 
over brain function and, in turn, trains the capacity to self-regulate associated behaviours (e.g., 
deficits of attention or insomnia). To date, however, few studies have included the necessary 
control groups and experimental designs to directly test this hypothesis. Of the thousands of 
published reports on the topic of neurofeedback, the recent effort by Schabus et al. stands out as 
one of the few randomized, double-blind, sham-controlled trials. Their findings show that 
neurofeedback may work for reasons very different from what conventional wisdom might 
suggest. 
Contrary to their hypotheses, Schabus et al. found little difference in insomnia outcomes 
when comparing genuine to sham neurofeedback (see Figure 1). For one phase of the 
experiment, the researchers provided sham (i.e., placebo) feedback from alternating frequency 
bands outside the range of interest. Such sham controls are crucial for teasing apart the effects of 
genuine feedback from other non-specific influences involving motivation and expectation. In 
this study, however, genuine and sham neurofeedback propelled comparable improvements in 
subjective ratings of wellbeing and restfulness.  
 
 
Figure 1. Comparing genuine and sham neurofeedback. 
 
In the study by Schabus et al., participants received real-time feedback concerning their own brain 
activity: the more they successfully amplified the target neural signal, the farther the needle rotated on 
the monitor in front of them. Participants underwent 12 sessions of genuine neurofeedback followed by 
a washout period of three months, and then 12 sessions of sham neurofeedback (or vice versa). 
Whereas neural regulation improved in the genuine feedback group, neither genuine nor sham 
interventions improved objective measures of sleep quality. Moreover, in terms of subjective reports, 
genuine and sham feedback led to comparable improvements. 
 
Crucially, whereas genuine neurofeedback helped participants amplify a subset of brain 
signals during training, this ability was independent of behavioural improvement. 
Neurofeedback, moreover, had no significant impact on either resting-state brain activity or sleep 
activity as measured by polysomnogram. These findings hold special importance in a field that 
often relies on subjective measures of improvement and rarely probes whether participants 
actually master control over brain activity. The reported results also call into question the 
standard 20- to 40-session regimen that dominates the neurofeedback landscape; the capacity for 
neural self-regulation seems to plateau after only a few sessions. This well-conceived (and 
reasonably-powered) study indicates that placebo factors play a central role in shaping the 
therapeutic outcomes associated with neurofeedback—more central perhaps than the role of 
brain feedback per se. 
When prescribing neurofeedback, practitioners must consider what constitutes 
meaningful clinical improvement: brain changes, subjective reports, objective measures, or some 
combination thereof. The positive subjective outcomes Schabus et al. observed might appear 
sufficient to advocate for neurofeedback; after all, the sleep complaints, which led individuals to 
seek help, subsided. Objectively, however, poor sleep quality, which remained unaltered, often 
leads to deleterious health consequences. Thus, subjective improvements may satisfy patients in 
the short-term while carrying the potential to inflict future harm by impeding further treatment.  
Proponents of neurofeedback may protest that this experiment reflects only one particular 
application of the technique. Perhaps a different frequency band, clinical condition, imaging 
modality, or number of sessions could lead to entirely different results. While this argument 
might hold true, the burden of proof continues to linger in the court of those who advocate for 
such claims (Thibault and Raz, 2016). To be sure, nascent forms of neurofeedback—e.g., 
leveraging functional MRI, large-scale connectivity analysis, or multivariate decoding 
algorithms (Cortese et al., 2016; Sitaram et al., 2016)—may eventually surpass the limitations of 
traditional EEG-based approaches. And yet, until we obtain independently replicable evidence 
supporting the benefits of neurofeedback over sham controls in double-blind randomized trials, 
the clinical efficacy of such interventions remains in question. 
Neurofeedback may nonetheless offer a potent psychosocial intervention, even if genuine 
feedback rarely outperforms rigorous sham variations (Thibault and Raz, in press). Placebo 
responses can be powerful, and they are not all equal. Coloured pills work better than white pills; 
large pills work better than small pills; and expensive pills work better than cheap ones. 
Moreover, two placebo pills relieve pain more effectively than one; placebo injections work 
better than placebo pills; and placebo surgeries trump all of the above (Raz and Harris, 2016). 
Whether real or sham, neurofeedback demands high engagement and immerses patients in a 
seemingly cutting-edge technological environment over many recurring sessions. Moreover, this 
form of neuroenchantment likely holds special sway over critical reasoning and can lead people 
to accept explanations they would normally dismiss (Ali et al., 2014). In this regard, 
neurofeedback may represent an especially powerful form of placebo intervention—a kind of 
superplacebo. On the one hand, this line of thought implies that the sham-control benchmark 
may be stricter in neurofeedback than in other clinical domains such as psychopharmacology. On 
the other hand, patients may well benefit more from neurofeedback placebo effects than from 
other available treatments. 
Neurofeedback relies heavily on “non-specific” mechanisms of healing (i.e., therapeutic 
influences peripheral to the supposed active ingredient of an intervention). Whereas clinical 
researchers often brush aside non-specific factors as nuisance variables, a subtler appreciation of 
these mechanisms could help practitioners offer better treatment. Contrary to what the name 
implies, non-specific factors can in fact lead to very specific psychological and physiological 
changes (Raz and Michels, 2007). Researchers can parse non-specific factors into discrete 
elements, such as the expectation to improve and the patient-practitioner interaction, each of 
which makes its own systematic contribution to outcomes (Kirsch et al., 2016). A more scientific 
understanding of the so-called “non-specific” elements that drive neurofeedback-mediated 
healing could help practitioners leverage and amplify these effects in neurofeedback as well as 
across other therapeutic domains. 
The appeal of neurofeedback may profit from the big business and salient vogue of the 
self-help boom in Western society. Unlike some extreme and dangerous forms of self-help, 
neurofeedback seems reasonable and requires neither self-parboiling nor arcane systems that 
supposedly merge the law of attraction with quantum physics (e.g., James Arthur Ray). And yet, 
we have to remain duly sceptical while also sufficiently open-minded. Neurofeedback may offer 
self-regulation techniques that are less about bettering the self than about creating try-on realities 
in which our unimproved self remains primordially unaltered; or it may actually instigate some 
meaningful changes of therapeutic value. Whether or not these are the only two options to 
ponder, we must constantly ask what kind of experimental evidence and solid science supports a 
claim. When it comes to self-help in the form of neurofeedback, insights from the science of 
placebos—a strange and counterintuitive domain—would be necessary to unlock the nuances of 
therapeutic outcomes (Thibault et al., 2015). 
Scientists must conduct rigorous studies and report their results, even if those end up 
incongruent with private hopes, prior expectations, or plausible theories. It gives us special 
pleasure, therefore, to see the non-significant findings of Schabus et al. (2017) featured in a 
flagship journal such as Brain. We must follow data, not belief. This sentiment takes on 
particular importance in the context of psychological research—a realm replete with file-drawer 
effects, inflated claims, and non-replicable findings (Open Science Collaboration, 2015). 
Selective reporting and publication bias likely weigh heavily on the field of neurofeedback 
(Thibault and Raz, in press) while also extending across pharmaceutical domains, the 
neurosciences, and scientific research as a whole. To identify the prevalence of these 
questionable practices, researchers could consider applying a “doping test for science”—a 
statistical trust-measure such as the R-index—to demonstrate replicability based on reported 
sample sizes and effects. We worry that such a test may reveal low replicability scores for the 
available neurofeedback studies.  
Even more important than replicability, however, is sound methodology. The present 
study advances the field of neurofeedback by demonstrating that well-controlled experiments are 
not only feasible but rather indispensable to elucidate how this contentious intervention promotes 
adaptive brain activity and desired behaviour. 
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